Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby, L. A. DiMeglio, M. S. Rendell, E. I. Felner, J. M. Dostou, S. E. Gitelman, C. M. Patel, K. J. Griffin, E. Tsalikian, P. A. Gottlieb, C. J. Greenbaum, N. A. Sherry, W. V. Moore, R. Monzavi, S. M. Willi, P. Raskin, A. Moran, W. E. Russell, A. Pinckney, L. Keyes-ElsteinM. Howell, S. Aggarwal, N. Lim, D. Phippard, G. T. Nepom, J. McNamara, M. R. Ehlers

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)S81-S82
JournalDiabetes Technology and Therapeutics
Volume17
DOIs
StatePublished - Feb 1 2015

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

Rigby, M. R., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., Raskin, P., Moran, A., Russell, W. E., Pinckney, A., ... Ehlers, M. R. (2015). Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Technology and Therapeutics, 17, S81-S82. https://doi.org/10.1089/dia.2015.1510